Novartis Announced Investigational Oral Therapy Iptacopan SSubstantially Reduced Both Intra- and Extravascular Hemolysis When Given as Monotherapy in a Phase Ii Study of Anti-C5 Naïve Paroxysmal Nocturnal Hemoglobinuria Patients
Novartis (NYSE: NVS) today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual Congress of the European Hematology Association (EHA).
